These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34636513)

  • 61. Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris.
    Tanghetti E; Dhawan S; Green L; Del Rosso J; Draelos Z; Leyden J; Shalita A; Glaser DA; Grimes P; Webster G; Barnett P; Le Gall N
    J Drugs Dermatol; 2010 May; 9(5):549-58. PubMed ID: 20480800
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Tazarotene cream for the treatment of facial photodamage: a multicenter, investigator-masked, randomized, vehicle-controlled, parallel comparison of 0.01%, 0.025%, 0.05%, and 0.1% tazarotene creams with 0.05% tretinoin emollient cream applied once daily for 24 weeks.
    Kang S; Leyden JJ; Lowe NJ; Ortonne JP; Phillips TJ; Weinstein GD; Bhawan J; Lew-Kaya DA; Matsumoto RM; Sefton J; Walker PS; Gibson JR
    Arch Dermatol; 2001 Dec; 137(12):1597-604. PubMed ID: 11735710
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis.
    Stein Gold L; Bagel J; Lebwohl M; Lin T; Martin G; Pillai R
    J Drugs Dermatol; 2018 Dec; 17(12):1290-1296. PubMed ID: 30586261
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study.
    Grimes P; Callender V
    Cutis; 2006 Jan; 77(1):45-50. PubMed ID: 16475496
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cutaneous pharmacokinetics of topically applied maxacalcitol ointment and lotion.
    Umemura K; Ikeda Y; Kondo K; Hirata K; Amagishi H; Ishihama Y; Tokura Y
    Int J Clin Pharmacol Ther; 2008 Jun; 46(6):289-94. PubMed ID: 18541125
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis.
    Lebwohl MG; Breneman DL; Goffe BS; Grossman JR; Ling MR; Milbauer J; Pincus SH; Sibbald RG; Swinyer LJ; Weinstein GD; Lew-Kaya DA; Lue JC; Gibson JR; Sefton J
    J Am Acad Dermatol; 1998 Oct; 39(4 Pt 1):590-6. PubMed ID: 9777766
    [TBL] [Abstract][Full Text] [Related]  

  • 67. An Open-Label Pilot Study to Investigate Safety and Efficacy of Fixed Combination Tazarotene 0.045% and Halobetasol Propionate 0.01% Lotion for the Treatment of Scalp Psoriasis.
    Ozyurekoglu E; Kircik L
    J Drugs Dermatol; 2021 Nov; 20(11):1191-1194. PubMed ID: 34784123
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Tazarotene foam versus tazarotene gel: a randomized relative bioavailability study in acne vulgaris.
    Jarratt M; Werner CP; Alió Saenz AB
    Clin Drug Investig; 2013 Apr; 33(4):283-9. PubMed ID: 23456673
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Tretinoin 0.05% Lotion for the Once-Daily Treatment of Moderate and Severe Acne Vulgaris in Females: Effect of Age on Efficacy and Tolerability.
    Stein Gold L; Pariser DM; Guenin E
    J Drugs Dermatol; 2019 Dec; 18(12):1218-1225. PubMed ID: 31860209
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tolerability comparison of adapalene gel, 0.3% versus tazarotene cream, 0.05% in subjects with healthy skin.
    Dosik JS; Arsonnaud S
    J Drugs Dermatol; 2007 Jun; 6(6):632-8. PubMed ID: 17668529
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cumulative irritation potential of adapalene 0.1% cream and gel compared with tazarotene cream 0.05% and 0.1%.
    Dosik JS; Homer K; Arsonnaud S
    Cutis; 2005 May; 75(5):289-93. PubMed ID: 15984630
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pharmacokinetic Profile, Safety, and Tolerability of Clascoterone (Cortexolone 17-alpha propionate, CB-03-01) Topical Cream, 1% in Subjects With Acne Vulgaris: An Open-Label Phase 2a Study.
    Mazzetti A; Moro L; Gerloni M; Cartwright M
    J Drugs Dermatol; 2019 Jun; 18(6):563. PubMed ID: 31251549
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Topical Film-Forming Solid Solutions for Enhanced Dermal Delivery of the Retinoid Tazarotene.
    Kapoor K; Gräfe N; Herbig ME
    J Pharm Sci; 2022 Oct; 111(10):2779-2787. PubMed ID: 35436468
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Safety and Efficacy of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Lotion in the Treatment of Moderate-to-severe Plaque Psoriasis: A Comparison with Halobetasol Propionate 0.05% Cream.
    Bhatia ND; Pariser DM; Kircik L; Lin T; Harris S; Mathew L; Pillai R
    J Clin Aesthet Dermatol; 2018 Nov; 11(11):15-19. PubMed ID: 30588269
    [No Abstract]   [Full Text] [Related]  

  • 75. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis.
    Guenther LC; Poulin YP; Pariser DM
    Clin Ther; 2000 Oct; 22(10):1225-38. PubMed ID: 11110233
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comparison of clinical efficacy of topical tazarotene 0.1% cream with topical clobetasol propionate 0.05% cream in chronic plaque psoriasis: a double-blind, randomized, right-left comparison study.
    Angelo JS; Kar BR; Thomas J
    Indian J Dermatol Venereol Leprol; 2007; 73(1):65. PubMed ID: 17319037
    [TBL] [Abstract][Full Text] [Related]  

  • 77. In vitro-in vivo correlation study for the dermatopharmacokinetics of terbinafine hydrochloride topical cream.
    Saeheng S; Nosoongnoen W; Varothai S; Sathirakul K
    Drug Dev Ind Pharm; 2013 Sep; 39(9):1372-7. PubMed ID: 23057672
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Simultaneous determination of tazarotene and its active metabolite tazarotenic acid in minipig plasma by LC-MS/MS and its application in pharmacokinetic study after topical administration of tazarotene gel.
    Tong Y; Pan H; Sun C; Xin X; Ding L; Ma P
    J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Jan; 978-979():173-8. PubMed ID: 25550192
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Optimizing treatment with topical tazarotene.
    Guenther LC
    Am J Clin Dermatol; 2003; 4(3):197-202. PubMed ID: 12627995
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study.
    Leyden J; Thiboutot DM; Shalita AR; Webster G; Washenik K; Strober BE; Shupack J
    Arch Dermatol; 2006 May; 142(5):605-12. PubMed ID: 16702498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.